Sequencio Therapeutics to Present Two Cancer Vaccine Studies at SITC 2026

Sequencio Therapeutics Company Limited, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., announced that the Society for Immunotherapy of Cancer (SITC) has selected two abstracts for presentation at its 41st Annual Meeting, taking place 4-8 November 2026 in Phoenix, Arizona. The studies evaluate key elements of Sequencio's Prime–Infiltrate–Ignite–Translate (PINT) translational research framework, with both vaccines generating targeted immune responses against their intended cancer-related targets. The TROP2 vaccine combination increased activated T cells within tumours, while the PD-L1/PRAME vaccine increased tumour-infiltrating immune cells and other indicators of local immune activity. Both studies demonstrated meaningful tumour growth inhibition, and the PD-L1/PRAME vaccine also generated a durable antigen-specific immune response. The use of humanised preclinical models contributes to the Translate element by helping researchers assess how findings may be relevant to humans. The research was covered by Media OutReach Newswire.

Dr Melvin Toh, Vice President & Chief Scientific Officer of CK Life Sciences, expressed that the two posters being presented at SITC 2026 provide an important opportunity to share new data from the lead cancer vaccine programmes with the international immuno-oncology community. The findings provide preclinical evidence supporting the intended mechanisms of action of the cancer vaccines and demonstrate how these programmes may generate and sustain anti-tumour immune responses. Dr Toh added that while the two programmes take distinct approaches, both are designed to engage multiple elements of the PINT framework. One explores combining tumour-targeted vaccination with checkpoint inhibition, while the other integrates tumour recognition and immune modulation within a single vaccine design. The findings may also help inform future clinical development in peri-operative settings, where lower tumour burden may give vaccine-induced immunity a greater opportunity to control residual disease.

The two poster presentations are: CKLS118 TROP2 circRNA-LNP Cancer Vaccine (Abstract Number: 583), titled 'Enhanced Anti-tumor Efficacy of an hTROP2 circRNA-LNP Vaccine Combined with Anti-PD-1 Therapy in TROP2+ Tumor Models', and CKLS202 PD-L1/PRAME Dual-Antigen Cancer Vaccine (Abstract Number: 1045), titled 'Dual-antigen cancer vaccine co-targeting human PD-L1 and PRAME induces specific immune responses in hPD-1/hPD-L1/HLA-A2.1 mice and inhibits tumor growth in an HLA-A2.1/hPRAME mouse colon cancer model'. Both will be presented on 6 November 2026.